A prespecified secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials shows once-weekly semaglutide 2.4 mg lowered NT-proBNP and improved symptoms in obesity-related HFpEF. PICO summary and expert commentary.
Browsing: Semaglutide
Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.
Summary: In healthy Chinese adults (n=32), once-daily oral semaglutide escalated from 3 mg to 14 mg over 12 weeks demonstrated…
Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular…
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular…
Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous…
Summary: In adults with type 2 diabetes and chronic kidney disease on stable ACE inhibitor or ARB therapy, semaglutide 1.0…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles,…
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg)…